(UroToday.com) Drs. Colin Dinney, MD Anderson Cancer Center, and Peter Black, the University of British Columbia, started the meeting with a discussion regarding the history of bladder cancer research and Bladder Cancer Advocacy Network (BCAN). In particular, they discussed the advances in understanding the biology of the disease including recent advances regarding bacillus calmette-guerin (BCG) and BCG unresponsive disease including recent clinical trials.
More recently, molecular subtypes of muscle-invasive disease have now been further investigated in non-muscle invasive disease. However, much ongoing work is needed and the field overall in high-risk non-muscle invasive bladder cancer (NMIBC) is rapidly evolving at large. The clinical panel kicked off the meeting and was followed by the translational panel followed by a question/answer discussion.
Presented by: Colin Dinney, MD, Chairman, Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX
Peter Black, MD, Senior Research Scientist, Vancouver Prostate Centre, Associate Director, Clinical Research, Vancouver Prostate Centre, Professor, Department of Urologic Sciences, University of British Columbia
Written by: Stephen B. Williams, MD, Medical Director for High-Value Care; Chief of Urology, Professor, Director of Urologic Oncology, Director Urologic Research, The University of Texas Medical Branch at Galveston, TX at the 2020 Virtual Bladder Cancer Advocacy Network Think Tank 2020
Read Presentation by Colin Dinney: BCANTT 2020: Phase 3 Trial of Nadofaragene Firadenovec for High-Risk, BCG Unresponsive, Non-Muscle Invasive Bladder Cancer
Read: Presentation by Peter Black: BCANTT 2020: BCG Unresponsive High-risk Non-muscle Invasive Bladder Cancer
Watch: A Debate on The Management of BCG Unresponsive - Cystectomy Ineligible Bladder Cancer Patient: Pembrolizumab Vs. Nadofaragene Firadenovec - Arjun Balar & Peter Black
Watch: Results of the SUO CTC Phase III Nadofaragene Firadenovec Trial for BCG Unresponsive NMIBC - Colin Dinney
Watch: How to Define Treatment Failure After BCG Treatment for Nonmuscle-Invasive Bladder Cancer - Peter Black